AmacaThera named CIX Top 20 Early company

   Press Release
Top20 Amaca Thera FB

(TORONTO, Sept. 27, 2021) — Amacathera Inc. has been named a Canadian Innovation Exchange (CIX)’s Top 20 Early company for 2021.

The awards, part of the CIX Digital Summit, recognize Canada’s most innovative technology companies at both the early and growth-stage. The CIX TOP 20 Early category recognizes companies with net revenue of less than CAD $5 million and/​or who have raised less than $10 million. In 2021, the program received 492 applications.

We’re proud to be named a CIX Top 20 early company,” said Dr. Mike Cooke, CEO and co-founder. AmacaThera has had a landmark year in 2021, closing an oversubscribed $10.3M Series A and receiving Health Canada’s approval to advance our lead product, AMT-143, to Phase I clinical trials. The team has also worked hard to adapt to the ongoing challenges presented by the pandemic and are making great strides in refining our manufacturing processes.”

Co-founded in 2016 by Dr. Molly Shoichet and Dr. Mike Cooke, AmacaThera was spun out of Shoichet’s University of Toronto laboratory through the UTEST accelerator to commercialize novel hydrogels. The company’s lead product, AMT-143, aims to improve post-operative pain management with potential applicability to any surgical incision.

The company’s investors include Lumira Ventures, Viva BioInnovator, Sprout BioVentures, BDC Capital Women in Technology (WIT) Venture fund, Inveready, MBX Capital, CR Capital Management, StandUp Ventures and MaRS IAF.


About AmacaThera Inc.
AmacaThera is a clinical-stage biotechnology company developing a novel drug delivery platform to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer, and other hard‑to‑reach target areas.

About the Canadian Innovation Exchange (CIX)
CIX is an annual curation program and internationally recognized conference that showcases Canada’s most promising early-stage and scaling startups. Now in its 14th year, CIX-invited delegates include North American VCs, corporations, private equity investors and advisors. CIX is Canada’s largest tech startup investment conference.

More Recent News

AmacaThera CEO Mike Cooke accepted to adMare BioInnovations 2021-22 Executive Institute

   Press Release

adMare BioInnovations is pleased to announce the nine women and nine men from diverse backgrounds and representing a wide range of life science businesses across the country, selected to join this year’s adMare Academy Executive Institute.Read more

CBC's Quirks & Quarks features AmacaThera Co-Founder Dr. Molly Shoichet

   Media Coverage

ICYMI: Thanks to CBC's Quirks and Quarks for re-running this November 2020 interview with our co-founder, Dr. Molly Shoichet.Read more

Out of the lab molly

Out of the lab, into the marketplace

   Media Coverage

Globe and Mail features AmacaThera’s Series A financingRead more